Detected ·
Ceruvia Lifesciences
$8M—
Ceruvia Lifesciences received an additional $8M from founder and CEO Carey Turnbull's family office to support a Phase 1/2 trial of BOL-148 (non-hallucinogenic LSD derivative) for cluster headache, with the study planned to launch in Germany.
- Website
- —
- —
- Amount
- $8 000 000 USD
- Stage
- —
- Event
- Funding round
- Detected
- 2026-08-15 12:02:43 UTC
- Signal ID
- 102a652d-d708-47f1-9f2b-1d8bb2750536
As the API returns it
{
"id": "102a652d-d708-47f1-9f2b-1d8bb2750536",
"created_at": "2026-08-15T12:02:43.910812Z",
"company_name": "Ceruvia Lifesciences",
"company_website_url": null,
"company_linkedin_url": null,
"event_type": "funding",
"funding_amount": 8000000,
"funding_currency": "USD",
"funding_stage": null,
"message": "*Ceruvia Lifesciences received an additional $8M from founder and CEO Carey Turnbull's family office to support a Phase 1/2 trial of BOL-148 (non-hallucinogenic LSD derivative) for cluster headache, with the study planned to launch in Germany.*"
}